Literature DB >> 16187894

Rhabdomyolysis in patients with west nile encephalitis and meningitis.

Susan P Montgomery1, Catherine C Chow, Stephanie W Smith, Anthony A Marfin, Daniel R O'Leary, Grant L Campbell.   

Abstract

Since 1999, more than 6,500 cases of West Nile virus neuroinvasive disease (WNND) have been reported in the United States. Patients with WNND can present with muscle weakness that is often assumed to be of neurological origin. During 2002, nearly 3,000 persons with WNV meningitis or encephalitis (or both) were reported in the United States; in suburban Cook County, Illinois, with 244 persons were hospitalized for WNV illnesses. The objective of this investigation was to describe the clinical and epidemiological features of identified cases of WNV neuroinvasive disease and rhabdomyolysis. Public health officials investigated patients hospitalized in Cook County, and identified a subset of WNV neuroinvasive disease patients with elevated creatine kinase levels. Cases were defined as hospitalized persons with a WNV infection, encephalitis or meningitis, and rhabdomyolysis. Retrospective medical record reviews were conducted and data was abstracted with a standardized data collection instrument. Eight patients with West Nile encephalitis and one with West Nile meningitis were identified with rhabdomyolysis. Median age of the nine patients was 70 years (range, 45-85 years), and eight were men. For all nine patients, the peak CK level was documented a median of 2 days after hospitalization (range, 1-24 days). Median CK level during hospitalization for all case-patients was 3,037 IU (range, 1,153-42,113 IU). Six patients had history of recent falls prior to admission. Although the temporal relationship of rhabdomyolysis and neurological WNV illness suggested a common etiology, these patients presented with complex clinical conditions which may have led to development of rhabdomyolysis from other causes. The spectrum of WNV disease requires further investigation to describe this and other clinical conditions associated with WNV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187894     DOI: 10.1089/vbz.2005.5.252

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  8 in total

1.  Opsoclonus myoclonus syndrome: an unusual presentation for West Nile virus encephalitis.

Authors:  Aasim Afzal; Sahar Ashraf; Sadat Shamim
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

2.  A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus.

Authors:  Tsai-Yu Lin; Kimberly A Dowd; Carolyn J Manhart; Steevenson Nelson; Stephen S Whitehead; Theodore C Pierson
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

3.  Nonbacterial myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

4.  Neuromuscular manifestations of west nile virus infection.

Authors:  A Arturo Leis; Dobrivoje S Stokic
Journal:  Front Neurol       Date:  2012-03-21       Impact factor: 4.003

5.  Cognitive behavioural impairment with irreversible sensorineural deafness as a complication of West Nile encephalitis.

Authors:  Sunil Pradhan; Sucharita Anand; Surjyaprakash S Choudhury
Journal:  J Neurovirol       Date:  2019-03-22       Impact factor: 3.739

6.  A case of West Nile virus encephalitis accompanied by diabetic ketoacidosis and rhabdomyolysis.

Authors:  Zachary Burden; Madeline Fasen; Benjamin L Judkins; Carmen Isache
Journal:  IDCases       Date:  2019-02-13

Review 7.  A review of the epidemiological and clinical aspects of West Nile virus.

Authors:  Timothy J Gray; Cameron E Webb
Journal:  Int J Gen Med       Date:  2014-04-11

8.  Fever, Myositis, and Paralysis: Is This Inflammatory Myopathy or Neuroinvasive Disease?

Authors:  Aneeta R Kiran; Richard A Lau; Kim M Wu; Andrew L Wong; Philip J Clements; Emil R Heinze
Journal:  Case Rep Rheumatol       Date:  2016-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.